The global Hepatitis C drugs market size is USD xx billion in 2019 and projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Hepatitis C is a viral infection that causes severe damage such as inflammation of the liver and can spread through contaminated blood. The advanced stages of hepatitis C can also lead to liver damage, thereby creating severe health risks. The severity of hepatitis C has created a huge emphasis on the research and development of drugs associated with the treatment of this disease. Several new drugs have been launched in recent times, due to the high prevalence of hepatitis C across the world. Hepatitis C requires oral injections and dosages on a weekly basis, and it also has several side effects that can also lead to permanent damage. Increasing clinical trials and successful drug clearances have aided the overall growth of the global hepatitis C market. An increasing number of regulatory approvals will boost the global hepatitis C market in the forthcoming years
Market Growth Drivers
The escalating demand for hepatitis C drugs has yielded several regulatory approvals for associated drugs. Increasing regulatory approvals for related drugs and recombinant products will constitute an increase in the global hepatitis C drug market value in the coming years. The hepatitis C drugs industry has witnessed numerous drug approvals in recent years driven by the increasing fatality rate of the disease. In April 2019, the United States Food and Drug Administration passed approval for Mavyret for the treatment of hepatitis C in pediatric patients. The high prevalence of hepatitis C has created a need for efficient drugs at low cost. Increased Awareness and Innovation of New Drugs is likely to direct the Hepatitis C Treatment Market